News and Press Releases
Press releases
Health Canada Approves Amended Clinical Trial Application
Press ReleaseToronto, Ontario – June 26, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
Press ReleaseResearch Detailing Advantages of Rutherrin® PhotoDynamic Therapy in deadly brain cancer, GlioBlastoma Multiforme (“GBM”) to be Published in the Journal of Neuro-Oncology Advances Toronto, Ontario – June 25, 2019, Theralase® Techn...
Theralase® Releases 2018 Year End Audited Financial Statements
Press ReleaseToronto, Ontario – April 17, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated ...
Theralase Releases Amended and Restated 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – June 18, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
Theralase Releases 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – May 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
Press ReleaseToronto, Ontario – May 20, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseToronto, Ontario – May 13, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Press ReleaseToronto, Ontario – May 7, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo...
Theralase’s Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
Press ReleaseToronto, Ontario – May 6, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo...
Theralase Commences Phase II NMIBC Clinical Study
Press ReleaseToronto, Ontario – April 25, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
